Incidence, patient characteristics, mode of drug delivery, and outcomes of septic shock patients treated with vasopressors in the arise trial

Abstract

Introduction:To describe the utilization of vasopressors (VP) in patients enrolled in the Australasian Resuscitation In Sepsis Evaluation (ARISE) trial, and to explore the association between time to VP and 90-day mortality.Methods:The primary exposure variable was VP use after arrival in the emergency department (ED). Vasoactive agents considered as VP included: Norepinephrine, epinephrine, metaraminol, or vasopressin. Time-to-event analysis, multivariable logistic regression, and propensity-matched treatment effects modeling were used to assess the association between time to VP and 90-day mortality.Results:In total 1,102 of 1,588 patients (69%) in ARISE received VP at any point. The media..